Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022007890 - COMPOSITIONS AND METHODS FOR INHIBITING YTHDF1

Publication Number WO/2022/007890
Publication Date 13.01.2022
International Application No. PCT/CN2021/105208
International Filing Date 08.07.2021
IPC
A61K 31/7088 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
A61K 38/55 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
55Protease inhibitors
C07K 16/06 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
06from serum
A61K 39/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Applicants
  • SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES [CN]/[CN]
  • HANGZHOU LEADING EDGE PHARMACEUTICAL LTD. [CN]/[CN]
  • SHANGHAI KANGQIAN BIOTECHNOLOGY LIMITED [CN]/[CN]
Inventors
  • LUO, Cheng
  • XU, Meng
  • CHEN, Shijie
  • LI, Yilin
  • CHEN, Yantao
  • JIANG, Hualiang
  • CHEN, Kaixian
  • JIANG, Zhanpeng
Agents
  • SHANGHAI DIANSHI PARTNERS, P.C.
Priority Data
PCT/CN2020/10110609.07.2020CN
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) COMPOSITIONS AND METHODS FOR INHIBITING YTHDF1
(FR) COMPOSITIONS ET PROCÉDÉS D'INHIBITION DE YTHDF1
Abstract
(EN) Provided are compositions and methods for attenuating YTHDF1 activities, as well as compositions and methods for promoting immune responses. For example, a YTH N6-Methyladenosine RNA Binding Protein 1 (YTHDF1) attenuating agent, is provided wherein said agent comprises a compound, and when bound to YTHDF1, said compound binds to at least one residue of YTHDF1.
(FR) La présente invention concerne des compositions et des procédés pour atténuer les activités YTHDF1, ainsi que des compositions et des procédés pour stimuler des réponses immunitaires. Par exemple, l'invention concerne un agent atténuant la protéine de liaison d'ARN N6-méthyladénosine YTH 1 (YTHDF1), ledit agent comprenant un composé, et lorsque celui-ci est lié à YTHDF1, ledit composé se lie à au moins un résidu de YTHDF1.
Latest bibliographic data on file with the International Bureau